EVOMEDIS Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

EVOMEDIS General Information

Description

Developer of wound healing technologies designed to improve the treatment and monitoring of acute and chronic wounds. The company's platform develops tissue-engineered skin substitutes, non-invasive wound sensor dressings, and wound healing research services that support skin regeneration, monitor wound conditions, and advance therapeutic development, enabling healthcare providers and research organizations to enhance wound healing outcomes through regenerative medicine and real-time monitoring.

Contact Information

Website
www.evomedis.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • ZWT II 4.OG Stiftingtalstraße 14
  • Graz, 8010
  • Austria
+43 0316
Primary Industry
Biotechnology
Other Industries
Monitoring Equipment
Vertical(s)
Advanced Manufacturing, HealthTech, Life Sciences
Corporate Office
  • ZWT II 4.OG Stiftingtalstraße 14
  • Graz, 8010
  • Austria
+43 0316

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EVOMEDIS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 01-Mar-2021 Completed Clinical Trials - Phase 1
To view EVOMEDIS’s complete valuation and funding history, request access »

EVOMEDIS Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

EVOMEDIS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025180611-A1 Cellulose dressing and method to deliver hypochlorite to wounds Pending 27-Feb-2024
EP-4615576-A1 Cells being highly enriched in sasp factors, and composition comprising said cells Pending 16-Nov-2022
US-20260275282-A1 Cells being highly enriched in sasp factors, and composition comprising said cells Pending 16-Nov-2022
WO-2024104577-A1 Cells being highly enriched in sasp factors, and composition comprising said cells Inactive 16-Nov-2022 C12N5/0629

EVOMEDIS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EVOMEDIS Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
ZWT Accelerator/Incubator
To view EVOMEDIS’s complete investors history, request access »

Ready to get started?

Request a free trial

EVOMEDIS FAQs

  • When was EVOMEDIS founded?

    EVOMEDIS was founded in 2020.

  • Where is EVOMEDIS headquartered?

    EVOMEDIS is headquartered in Graz, Austria.

  • What is the size of EVOMEDIS?

    EVOMEDIS has 5 total employees.

  • What industry is EVOMEDIS in?

    EVOMEDIS’s primary industry is Biotechnology.

  • Is EVOMEDIS a private or public company?

    EVOMEDIS is a Private company.

  • What is EVOMEDIS’s current revenue?

    The current revenue for EVOMEDIS is .

  • Who are EVOMEDIS’s investors?

    ZWT has invested in EVOMEDIS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process